Fluconazol como alternativa terapéutica en infecciones asociadas a Mycobacterium tuberculosis

• Main Authors: Sandrea L, Ramírez C, Romay Z
• Format: Article in Journal/Newspaper
• Language: English; Spanish
• Published: Universidad del Zulia,Facultad de Medicina,Departamento de Enfermedades Infecciosas y Tropicales 2018
• Subjects: pruebas de sensibilidad microbiana; fluconazol; Mycobacterium tuberculosis; rifampicina; isoniazida; microbial sensibility test; fluconazole; rifampin; isoniazid; Arctic medicine. Tropical medicine; RC955-962; Public aspects of medicine; RA1-1270; Arctic
• Online Access: https://doaj.org/article/f2c2446904c14df8bd10b0849bfa34ed

Abstract: Mycobacterium tuberculosis (M. tuberculosis) is a microorganism whose importance as an infectious agent has remained over the years but which has become a recent emergency and a serious public health problem in response to the evolution in its behavior against first-line antimicrobials, for its treatment and the emergence of multi-resistant strains, which require the use of therapeutic alternatives that allow its control. The objective of the work was to evaluate the in vitro behavior of M. tuberculosis before the antifungal agent fluconazole, for its possible use as a therapeutic alternative. To this, six strains were evaluated M. tuberculosis: 2 resistants to rifampicin, 2 resistants to isoniazid and 2 sensitive to both antimicrobials. We used the method of Minimum Inhibitory Concentration, using the microplate technique with Alamar Blue and the tube technique. Both methodologies showed sensitivity to low concentrations of fluconazole (0.0625 μg/ml). All strains were sensitive to the fluconazole / isoniazid combination; whereas, when exposed to the fluconazole / rifampicin combination, the strains showed resistance, indicating the antagonistic effect of rifampicin on fluconazole. The results allow us to conclude and suggest the possible therapeutic use of fluconazole against infections associated with M. tuberculosis. Resumen: Mycobacterium tuberculosis (M. tuberculosis) es un microorganismo cuya importancia como agente infeccioso ha permanecido a través de los años, pero que se ha convertido en una emergencia y un grave problema de salud pública, como respuesta a la evolución en su comportamiento ante los antimicrobianos de primera línea para su tratamiento y al surgimiento de cepas multi-resistentes, lo que amerita el uso de alternativas terapéuticas que permitan su control. El objetivo del trabajo fue evaluar el comportamiento in vitro de M. tuberculosis ante el antimicótico fluconazol, para su posible uso como alternativa terapéutica. Para ello, se evaluaron 6 cepas de M. tuberculosis: 2 ...